New drug design methodologies allow us to contemplate designer medicines for
very small groups of patients or even individuals. The future holds
promise for the rare disease community because modern biotech can build
bespoke (customized) therapies. Are we at the dawn of personalized
treatments being widely available for individual patients? This poses a
broader question: Just as every person is unique, could all medicines
become so too?

This podcast is the audio recording of a webinar launched by AAAS / Science Magazine and Fondation Ipsen.

With:

Genine Winslow, M.Sc. (Chameleon Biosciences, San Anselmo, CA)
Tiina Urv, Ph.D. (National Institutes of Health, Bethesda, MD)
Viviana Giannuzzi, Pharm.D., Ph.D. (Fondazione Gianni Benzi Onlus, Bari, Italy)
Sean Sanders, Ph.D. (Science/AAAS, Washington, DC)

Hosted on Ausha. See ausha.co/privacy-policy for more information.